Article Versions Notes

Tokumo K, Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, et al. Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial–Mesenchymal Transition. Cancers. 2023; 15(4):1092. https://doi.org/10.3390/cancers15041092

Tokumo, Kentaro, Takeshi Masuda, Taku Nakashima, Masashi Namba, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Shintaro Miyamoto, Hiroshi Iwamoto, Kazunori Fujitaka, and et al. 2023. "Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial–Mesenchymal Transition" Cancers 15, no. 4: 1092. https://doi.org/10.3390/cancers15041092

Tokumo, K., Masuda, T., Nakashima, T., Namba, M., Yamaguchi, K., Sakamoto, S., Horimasu, Y., Miyamoto, S., Iwamoto, H., Fujitaka, K., Miyata, Y., Okada, M., Hamada, H., & Hattori, N. (2023). Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial–Mesenchymal Transition. Cancers, 15(4), 1092. https://doi.org/10.3390/cancers15041092